Guyer

David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund

Retrieved on: 
Monday, April 5, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Optical, Health, Clinical trials, Guyer, ISEE

IVERIC bio, Inc. (Nasdaq: ISEE) today announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years, effective following Iveric Bios 2021 Annual Stockholder Meeting scheduled to be held on May 19, 2021.

Key Points: 
  • IVERIC bio, Inc. (Nasdaq: ISEE) today announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years, effective following Iveric Bios 2021 Annual Stockholder Meeting scheduled to be held on May 19, 2021.
  • Dr. Guyer will rejoin SV Health Investors as a Venture Partner having previously been both a Venture Partner and Partner at SV.
  • I will rejoin SV Health Investors where I will be able to focus on new company generation and board service.
  • Davids contributions to Iveric Bio have been significant, stated Axel Bolte, Member of the Board of Iveric Bio.

NGM Bio Announces Appointment of Shelly Guyer to Board of Directors

Retrieved on: 
Thursday, December 5, 2019
NGM, Guyer, Board of directors, Business, Articles, Private law

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced the expansion of its Board of Directors with the appointment of Shelly Guyer, who currently serves as Chief Financial Officer (CFO) of Invitae Corporation (NYSE: NVTA).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced the expansion of its Board of Directors with the appointment of Shelly Guyer, who currently serves as Chief Financial Officer (CFO) of Invitae Corporation (NYSE: NVTA).
  • We are thrilled to welcome Shelly to our Board of Directors, said David J. Woodhouse, Ph.D., Chief Executive Officer of NGM Bio.
  • Ms. Guyer said, I am delighted to join NGMs Board of Directors, having followed the companys progress and emergence as an increasingly prolific research and development organization with an impressive clinical stage pipeline.
  • Ms. Guyer holds an AB from Princeton University and an MBA from the Haas School of Business, University of California, Berkeley.